ZA892464B - Composition and method for acceleration of clot lysis - Google Patents

Composition and method for acceleration of clot lysis

Info

Publication number
ZA892464B
ZA892464B ZA892464A ZA892464A ZA892464B ZA 892464 B ZA892464 B ZA 892464B ZA 892464 A ZA892464 A ZA 892464A ZA 892464 A ZA892464 A ZA 892464A ZA 892464 B ZA892464 B ZA 892464B
Authority
ZA
South Africa
Prior art keywords
clot lysis
hapten
binding molecule
acceleration
composition
Prior art date
Application number
ZA892464A
Other languages
English (en)
Inventor
Guy L Reed
L Reed Guy
Gary Matsueda
Matsueda Gary
Edgar Haber
Haber Edgar
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of ZA892464B publication Critical patent/ZA892464B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Surgical Instruments (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Insulating Materials (AREA)
ZA892464A 1988-04-04 1989-04-04 Composition and method for acceleration of clot lysis ZA892464B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17722288A 1988-04-04 1988-04-04

Publications (1)

Publication Number Publication Date
ZA892464B true ZA892464B (en) 1989-12-27

Family

ID=22647707

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA892464A ZA892464B (en) 1988-04-04 1989-04-04 Composition and method for acceleration of clot lysis

Country Status (15)

Country Link
EP (1) EP0336693B1 (es)
JP (1) JP2871775B2 (es)
KR (1) KR100194113B1 (es)
AT (1) ATE114480T1 (es)
AU (1) AU628041B2 (es)
CA (1) CA1341377C (es)
DE (1) DE68919504T2 (es)
DK (1) DK174062B1 (es)
ES (1) ES2064435T3 (es)
FI (1) FI102812B (es)
GR (1) GR3015182T3 (es)
HU (1) HU207349B (es)
NO (1) NO301374B1 (es)
WO (1) WO1989009817A1 (es)
ZA (1) ZA892464B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JPH02268694A (ja) * 1989-04-07 1990-11-02 Teijin Ltd 血栓溶解剤
WO1998012329A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US6524675B1 (en) 1999-05-13 2003-02-25 3M Innovative Properties Company Adhesive-back articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735340B2 (ja) * 1985-05-23 1995-04-19 帝人株式会社 血栓溶解促進剤
BR8707308A (pt) * 1986-05-15 1988-09-13 Univ Emory Composicao fibrinolitica aperfeicoada e processo para a disolucao de coagulos em vasos sanguineos

Also Published As

Publication number Publication date
WO1989009817A1 (en) 1989-10-19
JP2871775B2 (ja) 1999-03-17
DK240190A (da) 1990-10-04
GR3015182T3 (en) 1995-05-31
ATE114480T1 (de) 1994-12-15
KR900700129A (ko) 1990-08-11
FI102812B1 (fi) 1999-02-26
KR100194113B1 (ko) 1999-06-15
DK240190D0 (da) 1990-10-04
AU628041B2 (en) 1992-09-10
NO904294L (no) 1990-12-04
ES2064435T3 (es) 1995-02-01
NO301374B1 (no) 1997-10-20
DE68919504T2 (de) 1995-06-29
JPH03504717A (ja) 1991-10-17
EP0336693A2 (en) 1989-10-11
HUT56394A (en) 1991-08-28
AU3284589A (en) 1989-11-03
EP0336693A3 (en) 1990-03-21
FI102812B (fi) 1999-02-26
NO904294D0 (no) 1990-10-03
HU207349B (en) 1993-03-29
DK174062B1 (da) 2002-05-13
DE68919504D1 (de) 1995-01-12
HU892304D0 (en) 1991-07-29
CA1341377C (en) 2002-07-16
EP0336693B1 (en) 1994-11-30
FI904867A0 (fi) 1990-10-03

Similar Documents

Publication Publication Date Title
Seitz et al. Increased thrombin activity during thrombolysis
Lijnen et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
DE3855096T2 (de) Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus
ZA892464B (en) Composition and method for acceleration of clot lysis
NO910811D0 (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
DK0519903T3 (da) Lægemiddel indeholdende aktiveret protein C
Marie-Claude Effect of rabbit thrombomodulin on thrombin inhibition by antithrombin in the presence of heparin
Marci et al. A review of the clinical indications for the plasma heparin assay
Eisenberg Role of new anticoagulants as adjunctive therapy during thrombolysis
Jang et al. A randomized, blinded study of two doses of Novastan®(brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study
Mirshahi et al. Effect of heparin and enoxaparin on platelet interaction with fibrin clots
Henriksson et al. Fatal iron intoxication with multiple coagulation defects and degradation of factor VIII and factor XIII
Preissner et al. Influence of fibrinogen on fibrin polymerization. Ultracentrifugation studies
VI PLATELET INHIBITORS IN ARTERIALTHROMBOSIS ANDATHEROCENESIS.
Aoki et al. Potentiation by synthetic fibrinolytic agents of vascular activator-and urokinase-induced lysis of human plasma clots as demonstrated by thrombelastography
Colucci et al. Does human protein C exert profibrinolytic activity?
Wikström et al. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase
Norman III. INHIBITORS OF THE FIBRINOLYTIC SYSTEM
Konttinen The effect of streptokinase on the plasma heparin thrombin time
Petäjä et al. 290 Fibrinolytic response to 10 and 20 minutes venous occlusion in healthy persons and in patients with idiopathic deep vein thrombosis
Ch et al. Influence of aspirin ingestion on in-vitro formation and lysis of platelet-fibrin-thrombi
Lindquist et al. The effect of antihistamine and antiserotonin on lung injuries in dogs having the microembolism syndrome
Fears et al. Evidence for the progressive uptake of APSAC by human clots in vitro
KATO et al. In vivo effects of snake venom on fibrinolytic system
Dyachenko Effect of Pulse Laser Hardening on Structure of High Speed Tool Steels